Features

What have been some key recent investments in manufacturing by the large bio/pharmaceutical companies? What areas, small-molecule APIs, biologics, or drug products, are targets of capital projects of the large companies? DCAT Value Chain Insights rounds up key projects.

The Pharmaceutical Research and Manufacturers of America (PhRMA), which represents innovator drug companies, has filed a complaint against the US government over drug-pricing reforms in the Inflation Reduction Act, which was signed into law last year.

Which companies have the highest ranked global supply-chain organizations? The Gartner Group’s annual study ranks the top 25 supply-chain organizations with four bio/pharma companies and one chemical company making the mark.

Notable drug shortages have made recent news. The FDA has issued its annual report on drug shortages by outlining the extent of drug shortages in calendar year 2022 and the steps it is taking to mitigate shortages.

As we near the mid-year mark, what have been the key moves—mergers and acquisitions, expansions, and new CDMOs entering the market—thus far in 2023? DCAT Value Chain Insights takes an inside look on what is on the industy’s radar.

Biotech companies are facing slowing capital flow in venture capital funding and IPOs, but will Big Pharma use its financial firepower to fund M&A to close its innovation deficit? 

Analysis of the top 10 mergers and acquisitions among bio/pharmaceutical companies thus far in 2023. Which companies and deals are most noteworthy and leading the way? 

How does sustainability and ESG (environmental, social and governance) goals and performance factor into companies’ strategies, operational focus, and financial disclosures? 

Teva’s President and CEO, Richard Francis, who assumed the helm of Teva in January, outlined this week the company’s new strategic framework to drive growth. The company’s Pivot to Growth strategy encompasses four main pillars to deliver short- and long-term growth from the company’s commercial portfolio and biosimilars, innovative pipeline, generics business, and focused capital allocation. 

Leaders in the European Union (EU) are addressing ways to mitigate drug shortages and supply-chain vulnerabilities in the EU with 19 EU member states supporting a Critical Medicines Act to reduce the EU’s dependence of non-EU countries for APIs, intermediates and other pharma ingredients. What other actions is the EU taking to mitigate supply-chain vulnerabilities?